Article Text

other Versions

PDF
Human papillomavirus prevalence in invasive cervical carcinomas in Bulgaria
  1. I Todorova1,
  2. G Ganchev2,
  3. E Shikova1
  1. 1Institute of Experimental Pathology and Parasitology, Bulgarian Academy of Sciences, Sofia, Bulgaria
  2. 2National Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria
  1. Correspondence to Professor Evelina Shikova, Institute of Experimental Pathology and Parasitology, Bulgarian Academy of Sciences, Acad.G.Bonchev Str. 25, 1113 Sofia, Bulgaria; evelina_sh{at}abv.bg

Abstract

Background Although Bulgaria has one of the highest rates of cervical cancer incidence and mortality in the EU, data on HPV type distribution are limited.

Aim To determine the prevalence of HPV types 16 and 18 in archival specimens from cervical cancer cases from Bulgaria.

Methods A total of 145 formalin-fixed, paraffin-embedded tissue samples from women with histologically proven invasive squamous cell carcinoma of the uterine cervix were available for this study. Detection of HPV types 16 and 18 was based on two parallel PCRs from each sample using type-specific primers for these genotypes. The quality of the extracted DNA was evaluated by PCR using PC03/PC04 β-globin-specific primers. Sections from each block were H&E stained and assessed by the study pathologist to confirm the histological diagnosis.

Results Of the 127 β-globin-positive squamous cell carcinoma cases, 98 (77.2%) were positive for HPV16 and/or HPV18 DNA. HPV16 was the more prevalent type and was found as a single infection in 86 (67.7%) cases. HPV type 18 as a single infection was detected in eight (6.3%) cases. Four specimens (3.2%) were double infected with HPV types 16 and 18.

Conclusions HPV types 16 and 18 are important risk factors for cervical cancer in Bulgaria. These data are helpful for estimating the potential impact of HPV vaccines in Bulgaria and indicate that ∼77% of cervical cancer cases in the country are potentially preventable by vaccination with currently available prophylactic HPV16/18 vaccines.

  • Cervical cancer
  • human papillomavirus
  • PCR
  • archival materials
  • Bulgaria
  • cancer research
  • HPV
  • PCR

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by the Bulgarian National Science Fund (Grant No L-1513/05).

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the ethics committee of the Institute of Neurobiology, Bulgarian Academy of Sciences.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.